Mezzion Reports Positive In Vivo Results for Udenafil in ADPKD

Data ReadoutpositiveudenafilPositive

AI Analysis

Summary

Mezzion Pharma announced positive in vivo results for udenafil, a PDE5 inhibitor, in a preclinical autosomal dominant polycystic kidney disease model.

Outcome Details

Positive in vivo results in preclinical ADPKD model

Importance:4/10

Sentiment:

0.70

preclinicalPDE5 inhibitorADPKDin vivo study

Related Companies

$INTI

Read the original article

Published by PR Newswire Pharma on August 2, 2026 3:13 PM

Read Original